In the Wake of 'Amgen v. Sanofi,' the USPTO Clarifies the Patent Enablement Requirement
On Jan. 10, the U.S. Patent and Trademark Office (USPTO) published guidelines on the enablement requirement under 35 U.S.C. 112(a) in view of the recent hallmark decision by the U.S. Supreme Court, Amgen v. Sanofi, 143 S. Ct. 1243 (2023) (Amgen). The …